446 related articles for article (PubMed ID: 30409415)
1. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
4. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
5. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
[TBL] [Abstract][Full Text] [Related]
6. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
7. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.
Richter MD; Pinkston O; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
Arthritis Rheumatol; 2018 Mar; 70(3):356-360. PubMed ID: 29363290
[TBL] [Abstract][Full Text] [Related]
9. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
[TBL] [Abstract][Full Text] [Related]
10. Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events.
Gente K; Diekmann L; Daniello L; Will J; Feisst M; Olsavszky V; Günther J; Lorenz HM; Souto-Carneiro MM; Hassel JC; Christopoulos P; Leipe J
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730272
[TBL] [Abstract][Full Text] [Related]
11. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer.
Melia A; Fockens E; Sfumato P; Zemmour C; Madroszyk A; Lafforgue P; Pham T
Joint Bone Spine; 2023 Jan; 90(1):105457. PubMed ID: 36116771
[TBL] [Abstract][Full Text] [Related]
12. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
14. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
16. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
18. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]